Proyectos Internacionales

Proyectos de Investigación

Proyectos abiertos

  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 831434
  • Programa/convocatoria: IMI2: CALL14: H2020-JTI-IMI2-2018-14-two-stage
  • Acrónimo: 3TR
  • Título: Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions
  • IP: Gómez Huelgas, Ricardo.
  • Grupo IBIMA: A-06
  • Centro de vinculación: HRUM
  • Sitio web proyecto: https://3tr-imi.eu/
  • Fecha inicio: 01/09/2019
  • Fecha fin: 31/08/2026
  • Rol en el proyecto:
  • Abstract: The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de Investigación
  • Organismo: Comisión Europea
  • Referencia: 768641
  • Programa/convocatoria: H2020-CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION 2017 (2): H2020-NMBP-X-KET-2017
  • Acrónimo: AllerScreening
  • Título: Point-of-care device base on KETs for diagnosis of food allergies
  • IP: Torres Jaén, María José
  • Grupo IBIMA: D-04
  • Centro de vinculación: HRUM
  • Sitio web proyecto: http://www.aller-screening.upm.es/index.php/en/
  • Fecha inicio: 01/10/2021
  • Fecha fin: 01/10/2021
  • Rol en el proyecto
  • Abstract: Food allergy is an immune-based disease that has become an important public health problem that affects children and adults and may be increasing in prevalence.In the US, food allergy affects 5% of children under the age of 5 years and 4% of teens and adults, and its prevalence appears to be on the increase. Globally, it is estimated that over 6% of the population, around 200 to 250 million people, suffer from some food allergies, affecting more than 17 million people only in Europe.The main objective of this proposal is translating an optical diagnostic technology already proven in which the novel AllerScreening platform is based on, to the clinical routine, addressing a priority healthcare unmet need from the laboratory to the clinic. The unique features of AllerScreening will allow clinicians to early detect main food allergies (at least the 90% of European food allergies) through a simple test using a drop of sera, reducing the cost and technical requirements of the current clinical practice. This new and innovative cost-effective sensing system for the in vitro component diagnosis of food allergies will be feasible thanks to the multiplexed disposable BioKits and the optical Pont-of-Care (PoC) reader in which the novel AllerScreening platform is based on, allowing the adoption of a novel PoC diagnostic device specific for food allergies.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 821283-2
  • Programa/convocatoria: H2020-EU.3.1.7. – Innovative Medicines Initiative 2 (IMI2): H2020-JTI-IMI2-2017-13-two-stage
  • Acrónimo: TRANSBIOLINE
  • Título: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • IP: Andrade Bellido, Raúl J.
  • Grupo IBIMA: D-05
  • Centro de vinculación: HUVV
  • Sitio web proyecto: https://transbioline.com/
  • Fecha inicio: 01/02/2019
  • Fecha fin: 31/01/2024
  • Rol en el proyecto:
  • Abstract: Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantial sample sizes are needed to ensure adequate case and control numbers, and robust evidence sufficient for qualification. To address this challenge, a consortium of leading European research institutions and SMEs has been established. The consortium will generate exploratory and confirmatory data enabling regulatory qualification of new safety biomarkers for application in drug development; establish robust datasets on the DILI, DIKI, DIPI, DIVI and DINI biomarkers to enhance diagnosis of disease; develop and validate assays for new safety biomarkers; implement profiles of circulating miRNAs as tissue and mechanism specific diagnostic tool; have key safety biomarkers accepted as qualified drug development tools by EMA, FDA, and PMDA. Given the significant expertise available across the consortium, the group will be able to tackle the key challenges related to successful biomarker qualification. A key driving principle of the consortium is cross-linking via existing networks of top profile research institutions, as well as capitalizing on existing data and resources. The Consortium is embedded into a network of international research collaborations such as the Pro-Euro-DILI-registry, TransQST, eTRANSAFE, the i2b2 tranSMART Foundation, the CIOMS DILI working group, EPoS, LITMUS, and BBMRI. To optimize regulatory interaction, we intend to continue our successful collaboration with non-European consortia such as PSTC, the FNIH Biomarkers Consortium, and US DILIN. A key expected result of the consortium will be a “Safety Biomarker Factory”, regularly qualifying new markers, with an associated “Safety Biomarker Warehouse”, providing to the scientific community, industry, and patients detailed data and information, and knowledge across a large spectrum of advanced safety biomarkers.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: CA17112
  • Programa/convocatoria: EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY (COST) 2017
  • Acrónimo: PRO-EURO DILI NET
  • Título: Prospective European Drug-Induced Liver Injury Network
  • IP: Andrade Bellido, Raúl J.
  • Grupo IBIMA: D-05
  • Centro de vinculación: HUVV
  • Sitio web proyecto: https://proeurodilinet.eu/
  • Fecha inicio: 16/10/2018
  • Fecha fin: 15/10/2022
  • Rol en el proyecto:
  • Estado: Cerrado
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: HP-PJ-2016-03
  • Programa/convocatoria3rd HEALTH PROGRAMME – CALL FOR PROPOSALS FOR PROJECTS 2016
  • Acrónimo: CHRODIS-PLUS
  • Título: CHRODIS-PLUS: Implementing good practices for chronic diseases
  • IP: Bedoya Belmonte, Juan José
  • Grupo IBIMA: F-14
  • Centro de vinculación: DS Málaga
  • Sitio web proyecto: http://chrodis.eu/
  • Fecha inicio: 01/09/2017
  • Fecha fin: 01/09/2020
  • Rol en el proyecto:
  • Abstract: CHRODIS PLUS is a three-year initiative (2017-2020) funded by the European Commission and participating organisations. Altogether. 17 policy dialogues and 21 implementation projects form the Action’s core: The policy dialogues (15 at the national level, and two at the EU level) increase awareness and acceptance in decision-makers in regards to improved actions for combatting chronic diseases. The pilot projects focus on the following areas: Health Promotion & Primary Prevention, an Integrated Multimorbidity Care Model, Fostering Quality Care for People with Chronic Diseases, ICT-based Patient Empowerment, and Employment & Chronic Diseases A heavy price for chronic diseases: it has been estimated that chronic diseases cost EU economies €115 billion or 0.8% of GDP annually. Approximately 70% to 80% of health care budgets across the EU are spent on treating chronic diseases. The EU and chronic diseases: Reducing the burden of chronic diseases such as diabetes, cardiovascular disease, cancer and mental disorders is a priority for EU Member States as well as at the EU Policy level, since chronic diseases affect 8 out of 10 people aged 65 and older in Europe. A wealth of knowledge exists within EU Member States on effective and efficient ways to prevent and manage cardiovascular disease, stroke and type-2 diabetes. Great potential exists for reducing the burden of chronic diseases by using this knowledge more effectively. The role of CHRODIS PLUS: CHRODIS PLUS, during its 36 months of operation will contribute to the reduction of this burden by promoting the implementation of policies and practices that have been demonstrated to be successful. The development and sharing of these tested policies and projects across EU countries is the core idea behind this action. The cornerstones of CHRODIS PLUS: This Joint Action raises awareness that in a health-promoting Europe – free of preventable chronic diseases, premature deaths and avoidable disabilities – initiatives in regards to chronic diseases should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of chronic diseases patient empowerment tackling functional decline and quality of life as the main consequences of chronic diseases making health systems sustainable and responsive to the ageing of our populations associated with the epidemiological transition.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: AC17/00112
  • Programa/convocatoria: EU-LAC HEALTH JOINT CALL ON HEALTH RESEARCH AND INNOVATION 2017
  • Acrónimo: FATZHEIMER
  • Título: HIGH FAT DIET, MICROBIOTA AND NEUROINFLAMMATION IN THE PROGRESSION OF ALZHEIMER DISEASE
  • IP: Rodríguez de Fonseca, Fernando
  • Grupo IBIMA: C-06
  • Centro de vinculación: HRUM
  • Fecha inicio: 01/01/2018
  • Fecha fin: 31/12/2021
  • Rol en el proyecto:
  • Abstract: CHRODIS PLUS is a three-year initiative (2017-2020) funded by the European Commission and participating organisations. Altogether. 17 policy dialogues and 21 implementation projects form the Action’s core: The policy dialogues (15 at the national level, and two at the EU level) increase awareness and acceptance in decision-makers in regards to improved actions for combatting chronic diseases. The pilot projects focus on the following areas: Health Promotion & Primary Prevention, an Integrated Multimorbidity Care Model, Fostering Quality Care for People with Chronic Diseases, ICT-based Patient Empowerment, and Employment & Chronic Diseases A heavy price for chronic diseases: it has been estimated that chronic diseases cost EU economies €115 billion or 0.8% of GDP annually. Approximately 70% to 80% of health care budgets across the EU are spent on treating chronic diseases. The EU and chronic diseases: Reducing the burden of chronic diseases such as diabetes, cardiovascular disease, cancer and mental disorders is a priority for EU Member States as well as at the EU Policy level, since chronic diseases affect 8 out of 10 people aged 65 and older in Europe. A wealth of knowledge exists within EU Member States on effective and efficient ways to prevent and manage cardiovascular disease, stroke and type-2 diabetes. Great potential exists for reducing the burden of chronic diseases by using this knowledge more effectively. The role of CHRODIS PLUS: CHRODIS PLUS, during its 36 months of operation will contribute to the reduction of this burden by promoting the implementation of policies and practices that have been demonstrated to be successful. The development and sharing of these tested policies and projects across EU countries is the core idea behind this action. The cornerstones of CHRODIS PLUS: This Joint Action raises awareness that in a health-promoting Europe – free of preventable chronic diseases, premature deaths and avoidable disabilities – initiatives in regards to chronic diseases should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of chronic diseases patient empowerment tackling functional decline and quality of life as the main consequences of chronic diseases making health systems sustainable and responsive to the ageing of our populations associated with the epidemiological transition.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 777389
  • Programa/convocatoria: IMI2-2016-10-04 – Creation of a pan-European Paediatric Clinical Trials Network
  • Acrónimo: conect4children
  • Título: CHRODIS-PLUS: COllaborative Network for European Clinical Trials For Children
  • IP: Urda Cardona, Antonio Luis
  • Grupo IBIMA: AE-19
  • Centro de vinculación: HRUM
  • Sitio web proyecto: https://conect4children.org/
  • Fecha inicio: 01/05/2018
  • Fecha fin: 30/04/2024
  • Rol en el proyecto:
  • Abstract: Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currently the potential of this effort is not realised. The conect4children (c4c) project will address the critical problems with the design, implementation and operational conduct of paediatric clinical trials, for example the fragmented and redundant efforts between sponsors, sites and countries. This project will generate a sustainable infrastructure that optimises the delivery of clinical trials in children through: a) a single point of contact for all sponsors, sites and investigators; b) efficient implementation of trials adopting consistent approaches, aligned quality standards and coordination of sites at national and international level; c) collaboration with specialist networks; d) high quality input to study design and preparation through rigorous strategic and operational feasibility assessment and e) the promotion of innovative methodologies. The project will be managed according to IMI2 best practice with a dedicated communications effort. The clinical trials infrastructure will be setup, implemented and tested by implementing 3-4 industry and at least 1 non-industry proof-of-viability studies. Expert advice groups will promote innovative methodologies and engagement with regulators. The business model for a sustainable infrastructure will be based on the European landscape of paediatric networks and available trial sites, the evaluation of services needs of sponsors of all kinds, and will be informed by the proof-of-viability studies. Supporting activities will include: data management (data about the trials and the network, including performance metrics for network management and promotion; handling trial data for non-industry sponsors; support for common data dictionaries); education and training. The voices of children, young people and their families will be central to the network..
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 825731
  • Programa/convocatoria: H2020-SC1-BHC-2018-2020 Novel patient-centred approaches for survivorship, palliation and/or end-of-life care
  • Acrónimo: iLIVE
  • Título: Living well, dying well. A research programme to support living until the end
  • IP: Martín Roselló, María Luisa
  • Grupo IBIMA: CA-15
  • Centro de vinculación: Fundación CUDECA
  • Sitio web proyecto: https://www.iliveproject.eu/
  • Fecha inicio: 01/01/2019
  • Fecha fin: 31/12/2021
  • Rol en el proyecto:
  • Abstract: Cumulative evidence suggests that food allergy (FA) is associated with a multitude of environmental factors including hygiene habits, antibiotic use, lifestyle changes and in particular, diet. Changes in nutrition can result in dysbiosis of the skin, gut and lung microbiota and generate changes in microbial metabolites produced, which may in turn produce epigenetic modifications. Current evidence supports the view that epigenetic mechanisms are involved in immune regulation and may represent a key-missing piece of the etiological puzzle for FA, at the interface between the environment and the genome. Dietary fibre can change the gut microbiota composition and therefore cause epigenome changes promoting health. Pectin is one type of dietary fibre that can exert immune regulation and mouse studies have shown its potential in preventing and even curing respiratory allergies. DIFAMEM aims to investigate the effects of FA treatment through intervention with a prebiotic dietary component, pectin, and using peach allergy as a model. This project will advance our understanding on how the interaction between dietary components and gut microbiota composition leads to epigenetic changes that provoke the immune modulation, and establish new strategies for dietary intervention in FA, with potential applications for other immune-related diseases.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: AC18/00031
  • Programa/convocatoria: ERA-HDHL JFA2 “Nutrition & the Epigenome” (Epigenome)
  • Acrónimo: DIFAMEM
  • Título: Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic interactions
  • IP: Torres Jaén, María José
  • Grupo IBIMA: D-04
  • Centro de vinculación: HRUM
  • Sitio web proyecto: https://www.healthydietforhealthylife.eu/index.php/projects/research-area-supported-project/report/223?s=1/
  • Fecha inicio: 01/01/2019
  • Fecha fin: 31/12/2021
  • Rol en el proyecto:
  • Abstract: Cumulative evidence suggests that food allergy (FA) is associated with a multitude of environmental factors including hygiene habits, antibiotic use, lifestyle changes and in particular, diet. Changes in nutrition can result in dysbiosis of the skin, gut and lung microbiota and generate changes in microbial metabolites produced, which may in turn produce epigenetic modifications. Current evidence supports the view that epigenetic mechanisms are involved in immune regulation and may represent a key-missing piece of the etiological puzzle for FA, at the interface between the environment and the genome. Dietary fibre can change the gut microbiota composition and therefore cause epigenome changes promoting health. Pectin is one type of dietary fibre that can exert immune regulation and mouse studies have shown its potential in preventing and even curing respiratory allergies. DIFAMEM aims to investigate the effects of FA treatment through intervention with a prebiotic dietary component, pectin, and using peach allergy as a model. This project will advance our understanding on how the interaction between dietary components and gut microbiota composition leads to epigenetic changes that provoke the immune modulation, and establish new strategies for dietary intervention in FA, with potential applications for other immune-related diseases.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 643638
  • Programa/convocatoria: TRANSCAN-2 Joint Transnational Call JTC-2017 “Translational Research on Rare Cancers”
  • Acrónimo: MOLCARUTUC
  • Título: Comprehensive genomic characterization of upper urinary tract urothelial carcinoma and paired bladder recurrences
  • IP: Herrera Imbroda, Bernardo
  • Grupo IBIMA: B-01
  • Centro de vinculación: HUVV
  • Sitio web proyecto: https://www.transcanfp7.eu/index.php/abstract/molcarutuc.html
  • Fecha inicio: 01/01/2019
  • Fecha fin: 01/01/2022
  • Rol en el proyecto:
  • Abstract: Background: Upper urinary tract urothelial carcinoma (UTUC) patients have poor outcomes and a high risk of future urothelial carcinoma of the bladder (UCB) after radical surgery. Currently, diagnostic tools that predict the risk of a UCB recurrence are lacking and more effective therapies are needed to improve survival. This project envisions the identification of novel genetic leads for improved diagnostics and therapy by large-scale genomic characterization of UTUC and paired UCB recurrences as the solution to address these clinical needs. Hypothesis: 1) UTUC and UCB recurrences are clonally related, enabling surveillance by molecular urine diagnostics. 2) UTUC is characterized by molecular alterations that lead to high tumor mutational burden (TMB), offering a target for immunotherapy. Aims: Primary: to clarify the clonal origin of UTUC and paired UCB recurrences. Secondary: to identify genomic alterations of UTUC and to investigate the potential of these aberrations as novel draggable targets and predictors of response to therapy. Methods: A retrospective cohort of 199 UTUC + 99 UCB recurrences (discovery set) and a prospective cohort of 170 UTUC samples (validation set) are compiled. Whole exome sequencing, microsatellite instability analysis, and immunohistochemistry are done to assess TMB, mismatch repair deficiency, immune infiltration and molecular subtypes. The genomic profile of UTUC and paired UCB is compared and molecular alterations of UTUC are correlated with clinical outcome and therapy response. Expected results and potential impact: This project provides novel insights on the clonality of UTUC and paired UCB. This can be applied to replace cystoscopies by patient-friendly urine assays for surveillance after surgery. Moreover, it enables the identification of new actionable genomic changes of UTUC that serve as targets for therapy, such as precision-guided immunotherapy in UTUC patients with high TMB leading to durable responses and improved outcome.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: AC19/00062
  • Programa/convocatoria: AAL-Actived Assisted Living Programme – AAL-2019 Sustainable Smart Solutions for Ageing well
  • Acrónimo: SELF
  • Título: Smart t-shirts for an Easier LiFe
  • IP: García Alegría, José Javier
  • Grupo IBIMA: CA-14
  • Centro de vinculación: HCS
  • Fecha inicio: 01/09/2020
  • Fecha fin: 31/12/2022
  • Rol en el proyecto:
  • Abstract: The aim of the SELF project is to improve the quality of life (QoL) of older adults by assisting them with an innovative ICT-based SELF system (made by a comfortable smart t-shirt, dry polimer sensors, data management platform, a mobile APP and advanced communications devices) that allows the accurate monitoring of vital signs and of functional capacity providing in real time reliable information about the health status of the elderly using the system. The t-shirts have advanced sensors embedded and are capable to dynamically monitor ECG and respiratory frequency, in relation to users’ life context and real activity. This system is connected to a central unit which directly transmit data to an APP which provides an alarm signal if some standards are overcome: in this way, the smart t-shirt could be the enabling factor for the implementation of a service of “Health surveillance and monitoring”. The application of the SELF system is expected to favour the development of active lifestyles by improving the SELF-efficacy and perceived autonomy of older adults, while serving as a monitoring and measurement tool to acquire information on mobility and health status. The solution also differentiates from conventional wearables due to the capacity of higher integration into elderly’s daily routines. It favors wearing compliance without requiring a change of behavior. Moreover, it minimizes the risk of stigmatization due to the unobtrusiveness of the embedded solution and thus the overall technology acceptance. This project intends to insert a trend of innovation, of international relevance, in contextualizing the new proposed technology with respect to a new logic of health monitoring, less invasive, reliable and consistent with the instances of “active life” of subjects who have the need or aspiration of continuous monitoring. The methodological endeavour of test therefore intends to operationally validate and scale-up in 4 different European countries the importance of the proposed ICT-based solution. The service related to the use of the t-shirt will be developed in collaboration with the end-users, following a well-designed co-creation approach, in order to tailor the t-shirt on the basis of individual needs. The SELF system will respond at market and commercial level to the needs of two specific target consumer typologies: baby boomers and alert stage. These two market categories will be addressed with tailored commercial strategies starting from the dissemination and exploitation activities of the project (WP4).
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: 210707
  • Programa/convocatoria: EIT HEALTH – Call for Proposals 2021
  • Acrónimo: R+
  • Título: Rehab+
  • IP: Gómez Doblas, Juan José
  • Grupo IBIMA: A-03
  • Rol en el proyecto:
  • Abstract: About a million people suffer a myocardial infarc􀆟on yearly in Europe. Without the right support, many pa􀆟ents fail to engage in much-needed lifestyle improvements and risk relapsing. Cardiac rehabilita􀆟on (CR) programs are successful in educa􀆟ng pa􀆟ents and lowering their CV risk. However, they don’t reach enough people (a􀆩endance before COVID19 between 8 and 50%) and their short dura􀆟on o􀅌en renders posi􀆟ve results not sustainable long term. The pandemic has accelerated the transforma􀆟on of post MI care and sharpened the need for high quality remote CR drama􀆟cally. Rehab+ is a mobile CR program, offered for one year to pa􀆟ents who cannot a􀆩end tradi􀆟onal CR. It offers an op􀆟mised digital pla􀆞orm, regular interac􀆟on with a health advisor and integra􀆟on with the healthcare team: the right educa􀆟onal environment for pa􀆟ents to establish lifestyle improvements and reduce CV risk long term. Rehab+ is being co-created with pa􀆟ents by rehab centers, Amgen and Liva.).
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: EURONANOMED2019-086
  • Programa/convocatoria: EURONANOMED3-European Innovative Research & Technological Development Projects in Nanomedicine – Joint Transnational call for Proposals 2019 (JTC 2019)
  • Acrónimo: DrNanoDAll
  • Título: Nanodiagnosis for Betalactam Hypersensitivity
  • IP: Torres Jaén, María José
  • Grupo IBIMA: D-04
  • Centro de vinculación: HRUM
  • Fecha inicio: 01/01/2020
  • Fecha fin: 31/12/2022
  • Rol en el proyecto:
  • Abstract: Betalactam (BL) allergy is self-reported by approximately 10% of the population with adverse drug reactions (ADR), being most frequently induced by an IgE mediated mechanism. This ADR has implications for patient safety and Health Systems costs since prescription of alternative antibiotics could induce bacterial resistance, could be more expensive and could potentially be more toxic. IgE-mediated BL allergy varies among patients, with some reacting to only one BL and others to several; it tends to change over time and differs between European countries, depending on BL consumption. BL allergy diagnosis is challenging, relying on patient clinical history, where previous BL-ADR evidence are often inaccurately reported, and on drug provocation and/or skin tests, which are not risk-exempt and require specialized healthcare professionals for results interpretation and patient management. In vitro testing stands out as the more rational alternative diagnostic method, showing however various limitations, such as low sensibility. Immunoassay for quantifying specific IgE is the most used, although limited to few BLs. Basophil activation test is also used, although the lack of knowledge about the activation mechanisms has hampered a wider clinical application. Thus, nowadays these tests do not fulfil the clinician’s needs. DrNanoDAll proposes the development of nanoparticles decorated with BL dendrimeric antigens, innovative solutions to surpass the current limitations. In order to offer new in vitro tools for BL-allergy accurate diagnosis, this proposal will combine nanotechnological and immunological approaches with BL-allergy clinical expertise, implementing a multi-omics workflow and involving the industry for scaling up nanomaterials and clinical test validation steps. This European-wide collaboration will be crucial to generate a new BL-allergy diagnosis tool suitable for personalized medicine, which will impact positively on the European Health Systems.
  • Estado: Abierto
  • Ámbito: UE
  • Tipo: Proyecto de investigación
  • Organismo: Comisión Europea
  • Referencia: AC19/00031
  • Programa/convocatoria: HDHL-INTIMIC – Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health)
  • Acrónimo: IKP
  • Título: Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health
  • IP: Torres Jaén, María José
  • Grupo IBIMA: D-04
  • Centro de vinculación: HRUM
  • Fecha inicio: 01/01/2020
  • Fecha fin: 30/06/2021
  • Rol en el proyecto:
  • Abstract: Studies suggest that the intestinal microbiome modulates the risk of several chronic diseases, including type 2 diabetes, allergy, cardiovascular disease, and colorectal cancer (CRC). Dietary factors are related to chronic disease risk, and they have been suggested to modulate the composition and function of the gut microbiome. However, detailed knowledge on the relationship of diet, the microbiome, and chronic disease risk is still limited. The overarching aim of the knowledge platform is to foster studies on the microbiome, nutrition and health by assembling available information in the field of microbiome research in food, nutrition and health in a comprehensive way, which also includes other disciplines (e.g. food science, metabolomics) that are relevant in the context of microbiome research. The goal is to make this information findable, accessible, interoperable and reusable (FAIR) to the scientific community and to link and provide in-depth information to various stakeholders. Through these efforts a network of transnational and multidisciplinary collaboration will emerge, that will further develop and increase the impact of microbiome research in human health. Urgent areas of research in this KP were identified to be the roles of microbiome in early infancy, during ageing and in subclinical and clinically manifest disease..
  • Estado: Abierto
  • Ámbito: Internacional no UE
  • Tipo: Proyecto de investigación
  • Organismo: FERRING Pharmaceuticals
  • Referencia: AC19/00031
  • Programa/convocatoria: FERRING COVID-19 INVESTIGATIONAL GRANTS 2020
  • Título: Placental injury and immune reaction transmitted to the neonates in cases of SARSCov2 infections. Study on placental and cord samples.
  • IP: González Mesa, Ernesto
  • Grupo IBIMA: CE-16
  • Centro de vinculación: HRUM
  • Fecha inicio: 01/07/2020
  • Fecha fin: 30/06/2021

Proyectos cerrados

  • Estado: Cerrado
  • Ámbito: UE
  • Tipo: RRHH
  • Organismo: Comisión Europea
  • Referencia: 600405
  • Programa/convocatoria: H2020- FP7/MSCA/COFUND/BEIPD
  • Acrónimo: BEIPD
  • Título: Be International Post-Doc – Euregio and Greater Region
  • IP: García Fuentes, Eduardo.
  • Grupo IBIMA: D-05
  • Centro de vinculación: HUVV
  • Sitio web proyecto: https://www.recherche.uliege.be/cms/c_11263942/fr/beipd-cofund
  • Fecha inicio: 01/02/2013
  • Fecha fin: 31/01/2019
  • Rol en el proyecto:

Recursos Humanos

Proyectos abiertos

  • Estado: Abierto
  • Ámbito: Internacional no UE
  • Tipo: RRHH
  • Organismo: IBRO (International Brain Research Organization)
  • Programa/convocatoria: IBRO Return Home Fellowships 2021li>
  • IP: García Díaz, Beatriz
  • Grupo IBIMA: C-01
  • Centro de vinculación: HRUM
  • Estado: Cerrado
  • Ámbito: UE
  • Tipo: RRHH
  • Organismo: Comisión Europea
  • Referencia: 600405
  • Programa/convocatoria: H2020- FP7/MSCA/COFUND/BEIPD
  • Acrónimo: BEIPD
  • Título: Be International Post-Doc – Euregio and Greater Region
  • IP: García Fuentes, Eduardo.
  • Grupo IBIMA: D-05
  • Centro de vinculación: HUVV
  • Sitio web proyecto: https://www.recherche.uliege.be/cms/c_11263942/fr/beipd-cofund
  • Fecha inicio: 01/02/2013
  • Fecha fin: 31/01/2019
  • Rol en el proyecto:
  • Estado: Cerrado
  • Ámbito: UE
  • Tipo: RRHH
  • Organismo: Comisión Europea
  • Programa/convocatoria: H2020- Call: International Mobility of Researchers – MSCA – IF
  • Título: Support of Professional Development
  • IP: Vandrovcova, Marta
  • Grupo IBIMA: F-01
  • Centro de vinculación: UMA
  • Fecha inicio: 01/02/2018
  • Fecha fin: 31/01/2020
  • Rol en el proyecto:
  • Estado: Cerrado
  • Ámbito: Internacional no UE
  • Tipo: RRHH
  • Organismo: EFDS
  • Programa/convocatoria: Albert Renold Travel Fellowship Programme
  • IP: Gutiérrez Repiso, Carolina
  • Grupo IBIMA: A-02
  • Centro de vinculación: HUVV
  • Estado: Cerrado
  • Ámbito: Internacional no UE
  • Tipo: RRHH
  • Organismo: European Molecular
  • Programa/convocatoria: SHORT-TERM FELLOWSHIPS 2018
  • IP: Hurtado Guerrero, Isaac
  • Grupo IBIMA: C-01
  • Centro de vinculación: HRUM
  • Rol en el proyecto:
  • Estado: Cerrado
  • Ámbito: UE
  • Tipo: RRHH
  • Organismo: Comisión Europea
  • Programa/convocatoria: ERASMUS+
  • IP: Pérez Pomares, José María / Cruciani, Sara
  • Grupo IBIMA: A-08
  • Centro de vinculación: UMA
  • Rol en el proyecto:

Otros proyectos

Proyectos abiertos

  • Estado: Abierto
  • Ámbito: Nacional
  • Organismo: Ministerio de Ciencia, Innovación y Universidades
  • Referencia: ECT2019-000575
  • Programa/convocatoria: Europa Redes y Gestores – Europa Centros tecnológicos del Subprograma Estatal de Generación de Conocimiento
  • Título: Redes y Gestores 2019
  • Fecha inicio: 01/01/2019
  • Fecha fin: 31/12/2021
  • Project Partners: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263